Observational study of people infected with SARS-Cov-2, treated with amantadine

• DOI: 10.1007/s43440-020-00168-1
• Publication Date: 2020-10-10T18:02:32Z
• Authors: Gonzalo Emiliano ...; José D. Aranda-Ma...; Ramiro Araújo; María Elena Herná...; Deissy Herrera-Co...; Fausto Rojas-Durán
• Keywords: Amantadine; Pharmacotherapy; Coronavirus

We conducted an observational study of 15 patients from a Southeastern area Mexico with symptoms compatible SARS-Cov-2, which were treated the antiviral amantadine. In this study, data collected individuals clinical COVID-19 infection, on ambulatory basis 100 mg amantadine for period 14 days. This drug demonstrated its effectiveness, as recovered successfully treatment without necessity attending hospital to use mechanical ventilation. All developed IgG antibodies SARS-Cov-2. Amantadine can be used viable and cost-effective alternative treating people severe acute respiratory syndrome (SARS-Cov-2) basis, while vaccine is not available.